Sun Pharma gets South Africa nod for generic semaglutide

Regulatory product approvalBusiness Updates View source PDF Explain this filing

SUNPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.4%Reaction day

₹1943.40

prior close

₹1955.00

announcement price

After-mkt

timing

Nifty 100market+0.2%+0.3% vs market

Pharmaceuticals peers, median of 165sector+0.0%+0.4% vs sector

On the reaction day the stock moved 0.3 pts more than Nifty 100 and 0.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.2

10m

-0.3

15m

-0.4

30m

-0.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.4+0.2+0.3+0.0+0.4

Next day

+0.4+0.1+0.3+0.0+0.4

-0.6+1.0-1.5-1.1+0.6

+0.8+0.8-0.0-0.5+1.3

+0.8+0.7+0.1-0.4+1.2

+0.0-0.1+0.1-1.7+1.7

-0.0-1.0+1.0-2.6+2.6

15d

-0.2+2.6-2.8-1.2+1.0

-3.2+1.5-4.6-0.4-2.7

-5.6-3.6-2.0-0.3-5.3

-9.2-4.4-4.8-2.2-7.0

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Sun Pharma received approval from South Africa's health regulator SAHPRA to manufacture and market generic semaglutide injection for adults with type 2 diabetes. The product will be a pre-filled multi-dose pen in two strengths for once-weekly dosing, with launch planned in coming days. South Africa is the second market after India where Sun Pharma has secured generic semaglutide approval. South Africa has a growing diabetes burden driven by urbanization and lifestyle changes.

Likely market impact

Opens a new market for Sun Pharma's generic semaglutide, expanding its international presence beyond India and supporting growth in emerging markets.